col0,col1,col2,col3,col4,col5,col6,col7
infliximab,Remsima,disease-modifying antirheumatic drug,Infliximab,3.75,Takayasu's arteritis,Australian pregnancy category C,chemical compound
denosumab,Prolia,bone density conservation agents,Denosumab,0.33,osteomalacia,Australian pregnancy category D,monoclonal antibody
infliximab,Remsima,disease-modifying antirheumatic drug,Infliximab,3.75,Takayasu's arteritis,US pregnancy categoryÂ B,monoclonal antibody
denosumab,Prolia,bone density conservation agents,Denosumab,0.33,gastroesophageal reflux disease,Australian pregnancy category D,chemical compound
infliximab,Flixabi,gastrointestinal agent,Infliximab,3.75,ankylosing spondylitis,Australian pregnancy category C,chemical compound
